Asthma, biologics, corticosteroids, and coronavirus disease 2019.
作者信息
Akenroye Ayobami T, Wood Robert, Keet Corinne
机构信息
Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
出版信息
Ann Allergy Asthma Immunol. 2020 Jul;125(1):12-13. doi: 10.1016/j.anai.2020.05.001. Epub 2020 May 6.
Abstract
摘要
相似文献
1
Asthma, biologics, corticosteroids, and coronavirus disease 2019.
Ann Allergy Asthma Immunol. 2020 Jul;125(1):12-13. doi: 10.1016/j.anai.2020.05.001. Epub 2020 May 6.
2
Common concerns in managing bronchial asthma during the COVID-19 pandemic.
Int J Tuberc Lung Dis. 2020 Jul 1;24(7):750-752. doi: 10.5588/ijtld.20.0378.
3
Assessment and management of adults with asthma during the covid-19 pandemic.
BMJ. 2020 Jun 8;369:m2092. doi: 10.1136/bmj.m2092.
4
Anaphylactic shock following the diagnosis of coronavirus disease 2019.
Ann Allergy Asthma Immunol. 2020 Oct;125(4):477-478. doi: 10.1016/j.anai.2020.07.032. Epub 2020 Aug 1.
5
COVID-19 in a patient with severe asthma treated with Omalizumab.
Allergy. 2020 Oct;75(10):2705-2708. doi: 10.1111/all.14456. Epub 2020 Jun 27.
6
Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.
J Cutan Med Surg. 2020 Jul/Aug;24(4):420-421. doi: 10.1177/1203475420929250. Epub 2020 May 25.
7
Successful treatment of coronavirus disease 2019 in a patient with asthma.
Allergy Asthma Proc. 2020 Jul 1;41(4):296-300. doi: 10.2500/aap.2020.41.200044.
8
Should biologics for psoriasis be interrupted in the era of COVID-19?
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
9
Should patients stop their biologic treatment during the COVID-19 pandemic.
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
10
[Drugs that aggravate the course of COVID-19 : really ?].
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):852-854.
引用本文的文献
1
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".
Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.
2
A retrospective study regarding the influence of COVID-19 disease on asthma.
BMC Pulm Med. 2023 Jan 17;23(1):22. doi: 10.1186/s12890-023-02309-7.
3
Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19.
Sci Rep. 2022 Oct 15;12(1):17313. doi: 10.1038/s41598-022-20176-w.
4
Understanding and Managing Severe Asthma in the Context of COVID-19.
Immunotargets Ther. 2021 Dec 11;10:419-430. doi: 10.2147/ITT.S342636. eCollection 2021.
5
The effects of the antecedent use of inhaled steroid on the clinical course of COVID-19: A retrospective study of asthmatic patients.
J Infect Public Health. 2022 Jan;15(1):56-64. doi: 10.1016/j.jiph.2021.12.003. Epub 2021 Dec 8.
6
The evidence is in that asthma is not associated with severe coronavirus disease 2019.
Ann Allergy Asthma Immunol. 2021 May;126(5):451-452. doi: 10.1016/j.anai.2021.02.023.
7
Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis.
J Asthma. 2022 May;59(5):866-879. doi: 10.1080/02770903.2021.1888116. Epub 2021 Apr 1.
8
Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview.
Nutrition. 2021 Jan;81:111016. doi: 10.1016/j.nut.2020.111016. Epub 2020 Sep 8.
9
Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases.
Clin Exp Allergy. 2020 Dec;50(12):1313-1324. doi: 10.1111/cea.13746. Epub 2020 Oct 6.
10
Authors' response.
Ann Allergy Asthma Immunol. 2020 Sep;125(3):362. doi: 10.1016/j.anai.2020.06.018.
本文引用的文献
1
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.
2
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.
Nat Med. 2020 Apr;26(4):453-455. doi: 10.1038/s41591-020-0819-2.
3
COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5. doi: 10.1016/j.jaip.2020.03.012. Epub 2020 Mar 26.
4
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
5
MERS, SARS and other coronaviruses as causes of pneumonia.
Respirology. 2018 Feb;23(2):130-137. doi: 10.1111/resp.13196. Epub 2017 Oct 20.
6
Viral infections and asthma: an inflammatory interface?
Eur Respir J. 2014 Dec;44(6):1666-81. doi: 10.1183/09031936.00047714. Epub 2014 Sep 18.
7
Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children.
J Allergy Clin Immunol. 2012 Aug;130(2):489-95. doi: 10.1016/j.jaci.2012.05.023. Epub 2012 Jul 4.
8
Role of viral respiratory infections in asthma and asthma exacerbations.
Lancet. 2010 Sep 4;376(9743):826-34. doi: 10.1016/S0140-6736(10)61380-3.
9
Asthma as a risk factor for invasive pneumococcal disease.
N Engl J Med. 2005 May 19;352(20):2082-90. doi: 10.1056/NEJMoa044113.
10
Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection.
Am J Respir Crit Care Med. 2000 Dec;162(6):2226-31. doi: 10.1164/ajrccm.162.6.2003019.
Zotero 插件